Hot Stocks
| ShowHide Related Items >><< - 03/23/23
- Gain sees dossier submission for Phase 1 clinical trial of GT-0228 by mid 2023
- 03/23/23
- Gain Therapeutics sees completion of IND enabling studies of GT-02287 in 1H 2023
- 03/21/23
- Gain Therapeutics announces grant award by Eurostars with Innosuisse
- 02/27/23
- Gain Therapeutics presents preclinical data from Gaucher Disease Program
- 03/27/23 Chardan
- Gain Therapeutics price target raised to $5.75 from $4 at Chardan
- 12/09/22 Chardan
- Gain Therapeutics initiated with a Buy at Chardan
- 11/25/22 Oppenheimer
- Gain Therapeutics price target lowered to $10 from $30 at Oppenheimer
- 11/14/22 H.C. Wainwright
- Gain Therapeutics price target lowered to $10 from $12 at H.C. Wainwright
- 03/23/23
- Gain Therapeutics reports FY22 EPS ($1.48), consensus ($1.51)
- 11/10/22
- Gain Therapeutics reports Q3 EPS (38c), consensus (46c)
|
Options
| ShowHide Related Items >><< - $98.41 /
+12.28 (+14.26%) - 03/28/23
- Alibaba rises 12.4%
- 03/28/23
- Alibaba to reorganize into six business groups and other investments
- 02/23/23
- Alibaba jumps 6% to $100.65 after Q3 results beat estimates
- 02/23/23
- Alibaba CEO sees 'continued recovery in consumer sentiment'
- 03/14/23
- CEO says AMC 'APE' conversion approved by shareholders
- 03/14/23
- AMC falls after investors approve increase in common shares
- 03/14/23
- AMC Entertainment trading resumes
- 03/14/23
- AMC shares fall 10% amid shareholder votes at special meeting
- 03/28/23
- NHTSA probing 50,000 Tesla Model Xs over seat belt malfunction
- 03/26/23
- Fly Intel: Top five weekend stock stories
- 03/23/23
- Cathie Wood's ARK Investment sold 140K shares of Tesla today
- 03/21/23
- EU passenger car registrations up 11.5% in February
- 03/28/23
- Google teams with AI firm Replit to aid generative AI for software development
- 03/28/23
- Semtech announces first LoRa-enabled third party products available
- 03/28/23
- Lifeist's Mikra debuts on Amazon.com
- 03/24/23
- User reports indicate problems at Amazon says Downdetector
- $98.41 /
+12.28 (+14.26%) - 07:17 Today Loop Capital
- Alibaba shares offer event-driven upside, says Loop Capital
- 05:57 Today JPMorgan
- JPMorgan 'blue sky scenario' has Alibaba worth $210 per share
- 03/28/23 Truist
- Truist sees Alibaba reorganization driving accountability, shareholder value
- 03/28/23 Morgan Stanley
- Alibaba named 'Research Tactical Idea' at Morgan Stanley
- 07:52 Today Wedbush
- Amazon unlikely to acquire AMC, says Wedbush
- 03/28/23 Raymond James
- EPR has upside if AMC were to be sold, says Raymond James
- 03/23/23 Citi
- AMC Entertainment resumed with a Sell at Citi
- 02/09/23 Macquarie
- Macquarie raises price target on top theatre pick for 2023
- 03/28/23 Deutsche Bank
- Tesla estimates lowered after price cuts at Deutsche Bank
- 03/27/23 Morgan Stanley
- Morgan Stanley says Tesla 20% auto gross margin may prove difficult beyond Q1
- 03/27/23 Citi
- Tesla price target raised to $192 from $146 at Citi
- 03/27/23 Barclays
- Tesla delivery beat in Q1 could be share catalyst, says Barclays
- 07:52 Today Wedbush
- Amazon unlikely to acquire AMC, says Wedbush
- 06:46 Today KeyBanc
- Microsoft price target raised to $316 from $270 at KeyBanc
- 03/28/23 Raymond James
- EPR has upside if AMC were to be sold, says Raymond James
- 03/24/23 Barclays
- Meta Platforms price target raised to $270 from $260 at Barclays
- $98.41 /
+12.28 (+14.26%) - 02/23/23
- Alibaba reports Q3 adjusted EPS $2.79, consensus $2.37
- 02/22/23
- Notable companies reporting before tomorrow's open
- 02/22/23
- Notable companies reporting before tomorrow's open
- 11/17/22
- Alibaba reports Q2 adjusted EPS $1.82, consensus $1.64
- 02/28/23
- AMC Entertainment reports Q4 adjusted EPS (14c), consensus (21c)
- 02/28/23
- Notable companies reporting after market close
- 11/08/22
- AMC Entertainment reports Q3 adjusted EPS (20c), consensus (25c)
- 03/02/23
- Aehr Test Systems reiterates annual guidance, comments on Tesla statements
- 01/25/23
- Tesla reports Q4 EPS $1.19, consensus $1.13
- 01/25/23
- Notable companies reporting after market close
- 10/19/22
- Tesla reports Q3 EPS $1.05, consensus 99c
- 02/02/23
- Amazon sees Q1 revenue $121B-$126B, consensus $125.11B
- 02/02/23
- Amazon reports Q4 EPS 3c with Rivian loss, consensus 17c
- 02/02/23
- Notable companies reporting after market close
- 10/27/22
- Amazon sees Q4 revenue $140B-$148B, consensus $155.15B
- $98.41 /
+12.28 (+14.26%) - 05:50 Today
- Alibaba reorganization triggers mass layoff fears, Nikkei Asia reports
- 03/28/23
- Alibaba plans to split into six main units, explore IPOs, Bloomberg reports
- 03/27/23
- Alibaba founder Jack Ma returns to China, Reuters reports
- 03/22/23
- Part of Alibaba shareholder lawsuit dismissed by judge, Reuters reports
- 03/28/23
- Amazon has 'NO deal on the table' for AMC Entertainment, FBN says
- 03/28/23
- AMC Entertainment up after blog post speculation on Amazon interest
- 03/14/23
- AMC shareholders approve 1-for-10 stock split, Bloomberg reports
- 03/14/23
- AMC holders approve increase to common shares, Bloomberg reports
- 03/28/23
- Second-hand Tesla cars losing value faster following price cuts, FT reports
- 03/23/23
- Canada budget to include tax credit for EV production equipment, Reuters says
- 03/23/23
- Tesla sees losing $7,500 federal tax credit on Model 3 SR, Electrek reports
- 03/21/23
- Grizzly Research reports short opinion on Sigma Lithium
- 03/28/23
- Amazon, Google will have to let U.K. radio stream on smart speakers, FT says
- 03/28/23
- Amazon has 'NO deal on the table' for AMC Entertainment, FBN says
- 03/28/23
- AMC Entertainment up after blog post speculation on Amazon interest
- 03/28/23
- Disney eliminates metaverse unit, cutting 50 jobs, WSJ reports
- $98.41 /
+12.28 (+14.26%) - 03/28/23
- What You Missed On Wall Street On Tuesday
- 03/28/23
- What You Missed On Wall Street This Morning
- 03/28/23
- Fly Intel: Pre-market Movers
- 03/27/23
- What You Missed On Wall Street This Morning
- 03/28/23
- What You Missed On Wall Street On Tuesday
- 03/23/23
- Street Wrap: Today's Top 15 Upgrades, Downgrades, Initiations
- 02/28/23
- Fly Intel: After-Hours Movers
- 12/28/22
- What You Missed On Wall Street This Morning
- 03/28/23
- What You Missed On Wall Street This Morning
- 03/27/23
- What You Missed This Week in EVs and Clean Energy
- 03/26/23
- Opening Day: Singapore's Ohmyhome makes Nasdaq debut
- 03/23/23
- What You Missed On Wall Street On Thursday
- 03/28/23
- What You Missed On Wall Street On Tuesday
- 03/26/23
- Box Office Battle: ‘John Wick: Chapter 4’ opens with huge $73.5M
- 03/20/23
- What You Missed On Wall Street On Monday
- 03/20/23
- What You Missed On Wall Street This Morning
- $98.41 /
+12.28 (+14.26%) - 08:00 Today
- Alibaba call buyer realizes 50% same-day gains
- 03/28/23
- Unusually active option classes on open March 28th
- 03/24/23
- Alibaba call volume above normal and directionally bullish
- 03/24/23
- Unusually active option classes on open March 24th
- 03/28/23
- AMC Entertainment call volume above normal and directionally bullish
- 03/15/23
- Notable open interest changes for March 15th
- 03/14/23
- Largest borrow rate increases among liquid names
- 03/06/23
- Largest borrow rate increases among liquid names
- 03/28/23
- Notable open interest changes for March 28th
- 03/24/23
- Notable open interest changes for March 24th
- 03/23/23
- Notable open interest changes for March 23rd
- 03/23/23
- Tesla put buyer realizes 137% same-day gains
- 03/28/23
- Notable open interest changes for March 28th
- 03/22/23
- Notable open interest changes for March 22nd
- 03/07/23
- Notable open interest changes for March 7th
- 03/03/23
- Notable open interest changes for March 3rd
|
Hot Stocks
|
Biogen reported Phase 1b… ShowHide Related Items >><< - 08:49 Today
- Ionis Pharmaceuticals' IONIS-MAPTRx shows tau reduction efficacy in Alzheimer's
- 03/22/23
- Biogen provides update on AdCom meeting on Tofersen for SOD1-ALS
- 03/22/23
- Inozyme appoints Matthew Winton as COO
- 03/20/23
- FDA posts briefing document for advisors' review of Biogen's ALS drug
- 03/21/23 BofA
- FDA briefing docs suggest FDA in favor of Biogen's tofersen, says BofA
- 03/17/23 Stifel
- Stifel trims Biogen target, but has more confidence lecanemab 'best-in-class'
- 03/13/23 RBC Capital
- Biogen price target raised to $350 from $335 at RBC Capital
- 03/09/23 BofA
- No ad com suggests positive potential outcome for Sage's zura, says BofA
- 02/15/23
- Biogen sees FY23 EPS $15.00-$16.00, consensus $15.72
- 02/15/23
- Biogen reports Q4 EPS $4.05, consensus $3.48
- 02/14/23
- Notable companies reporting before tomorrow's open
- 02/14/23
- Notable companies reporting before tomorrow's open
- 03/13/23
- VA to widely cover new Alzheimer's treatment from Eisai and Biogen, STAT says
- 01/11/23
- FDA Commissioner defends FDA's approval of Biogen's Aduhelm, WSJ reports
- 12/23/22
- Third trial death tied to Biogen and Eisai Alzheimer's drug, Science reports
- 11/28/22
- Second death linked to Eisai's lecanemab Alzheimer's drug, Science says
- 02/15/23
- What You Missed On Wall Street On Wednesday
- 02/15/23
- What You Missed On Wall Street This Morning
- 02/15/23
- Fly Intel: Pre-market Movers
- 01/20/23
- Fly Intel: Pre-market Movers
- 11/30/22
- Early notable gainers among liquid option names on November 30th
- 11/14/22
- Early notable gainers among liquid option names on November 14th
- 10/13/22
- Early notable gainers among liquid option names on October 13th
- 09/29/22
- Unusually active option classes on open September 29th
|
Initiation
| ShowHide Related Items >><< - 03/09/23
- Baxter treatment of short bowel syndrome granted FDA orphan designation
- 02/09/23
- Baxter falls -13.6%
- 02/09/23
- Baxter falls -10.1%
- 02/01/23
- Miromatrix Medical, Baxter enter research agreement for ALF
- 03/28/23 UBS
- Baxter initiated with a Neutral at UBS
- 02/13/23 Barclays
- Baxter price target lowered to $54 from $63 at Barclays
- 02/10/23 Cowen
- Baxter price target lowered to $45 from $70 at Cowen
- 02/06/23 KeyBanc
- Baxter price target lowered to $60 from $73 at KeyBanc
- 02/09/23
- Baxter sees FY23 adjusted EPS $2.75-$2,95, consensus $3.56
- 02/09/23
- Baxter sees Q1 adjusted EPS 46c-50c, consensus 76c
- 02/09/23
- Baxter reports Q4 adjusted EPS 88c, consensus 94c
- 02/08/23
- Notable companies reporting before tomorrow's open
- 03/20/23
- Thermo Fisher, Celltrion compete for Baxter's biopharma unit, Reuters says
- 03/21/23
- What You Missed On Wall Street On Tuesday
- 03/21/23
- What You Missed On Wall Street This Morning
- 02/09/23
- Fly Intel: Pre-market Movers
- 01/06/23
- What You Missed On Wall Street On Friday
- 02/21/23
- Baxter call volume above normal and directionally bullish
- 02/09/23
- Baxter put volume heavy and directionally bearish
- 01/24/23
- Baxter put volume heavy and directionally bearish
- 01/05/23
- Baxter call volume above normal and directionally bullish
|
Initiation
| ShowHide Related Items >><< - 07:10 Today
- STAAR Surgical names Warren Foust COO, Magda Michna, as chief of medical affairs
- 03/22/23
- Johnson & Johnson issues statement on Third Circuit review petition
- 03/15/23
- Janssen announces publication of data on dengue antiviral candidate
- 03/07/23
- Protagonist Therapeutics reports 'positive' results from FRONTIER 1 Phase 2b
- 03/28/23 UBS
- Johnson & Johnson initiated with a Neutral at UBS
- 03/13/23 Stifel
- Arcellx initiated with a Buy at Stifel
- 03/01/23 Guggenheim
- Johnson & Johnson initiated with a Neutral, $161 price target at Guggenheim
- 02/28/23 Guggenheim
- Johnson & Johnson initiated with a Neutral at Guggenheim
- 02/28/23
- Fate Therapeutics reports Q4 EPS (58c), consensus (86c)
- 01/30/23
- Johnson & Johnson to challenge federal appeals court ruling
- 01/24/23
- Johnson & Johnson sees FY23 adjusted EPS $10.45- $10.65, consensus $10.33
- 01/24/23
- Johnson & Johnson sees FY23 adjusted operational EPS $10.40-$10.60
- 02/01/23
- Novavax refuses to refund $700M for COVID shots never delivered, NY Times says
- 01/30/23
- Appeals court dismisses Chapter 11 case of J&J unit, WSJ reports
- 01/13/23
- Johnson & Johnson cuts production of Covid-19 vaccine, WSJ reports
- 01/09/23
- J&J may look for deals that boost eye care, surgical robots units, Reuters says
- 03/01/23
- Street Wrap: Today's Top 15 Upgrades, Downgrades, Initiations
- 01/30/23
- What You Missed On Wall Street On Monday
- 01/30/23
- What You Missed On Wall Street This Morning
- 01/24/23
- What You Missed On Wall Street On Tuesday
- 03/22/23
- Johnson & Johnson put volume heavy and directionally bearish
- 03/13/23
- Unusually active option classes on open March 13th
- 01/31/23
- Johnson & Johnson put buyer realizes 135% same-day gains
- 01/30/23
- Johnson & Johnson put volume heavy and directionally bearish
|
Hot Stocks
| ShowHide Related Items >><< UEEC United Health Products - 01/31/23
- UHP provides update on FDA PMA application, White Lion agreement
- 12/19/22
- United Health Products provides update on PMA application
- 11/28/22
- United Health to submit full PMA application following sample analysis review
- 10/31/22
- United Health Products provides update on PMA application
|
Initiation
| ShowHide Related Items >><< - 03/07/23
- Abbott: FDA clears first first commercially available TBI blood test
- 03/06/23
- DexCom down more than 7% after FDA gives nod to Abbott CGM sensors
- 03/06/23
- Abbott: FDA clears FreeStyle Libre 2, FreeStyle Libre 3 sensors
- 03/05/23
- Abbott announces late-breaking data from landmark COAPT trial
- 03/28/23 UBS
- Abbott initiated with a Buy at UBS
- 03/08/23 Jefferies
- DexCom pullback on Abbott news a buying opportunity, says Jefferies
- 03/08/23 Wells Fargo
- Wells downgrades Edwards Lifesciences with Medtronic gaining share
- 03/07/23 BofA
- BofA says buy DexCom on weakness after Abbott's Libre gets pump integration
- 01/25/23
- Abbott sees FY23 adjusted EPS $4.30-$4.50, consensus $4.40
- 01/25/23
- Abbott reports Q4 adjusted EPS $1.03, consensus 92c
- 01/24/23
- Notable companies reporting before tomorrow's open
- 01/24/23
- Notable companies reporting before tomorrow's open
- 01/22/23
- Abbott says cooperating with DoJ in baby formula probe, Bloomberg says
- 01/20/23
- DOJ investigating conduct at Abbott infant-formula plant, WSJ reports
- 02/22/23
- Diabetes management stocks slide on report of tech giant's breakthroughs
- 02/13/23
- Street Wrap: Today's Top 15 Upgrades, Downgrades, Initiations
- 02/09/23
- What You Missed On Wall Street On Thursday
- 02/09/23
- What You Missed On Wall Street This Morning
- 11/28/22
- Abbott put volume heavy and directionally bearish
- 10/07/22
- Early notable gainers among liquid option names on October 7th
- 10/06/22
- Abbott call volume above normal and directionally bullish
|
Hot Stocks
| ShowHide Related Items >><< IONS Ionis Pharmaceuticals - 03/27/23
- Ionis Pharmaceuticals announces NEURO-TTRansform study met co-primary endpoints
- 03/23/23
- Ionis says FDA advisors vote in favor of potential tofersen accelerated approval
- 03/07/23
- Ionis Pharmaceuticals: FDA accepts NDA for eplontersen
- 02/01/23
- Ionis Pharmaceuticals: GSK advances bepirovirsen into Phase 3 development
- 03/22/23
- Biogen provides update on AdCom meeting on Tofersen for SOD1-ALS
- 03/22/23
- Inozyme appoints Matthew Winton as COO
- 03/20/23
- FDA posts briefing document for advisors' review of Biogen's ALS drug
- 03/16/23
- Biogen receives favorable court ruling on TECFIDERA
IONS Ionis Pharmaceuticals - 03/21/23 Bernstein
- Ionis Pharmaceuticals initiated with an Underperform at Bernstein
- 02/23/23 SVB Securities
- Ionis Pharmaceuticals price target lowered to $27 from $34 at SVB Securities
- 02/23/23 Barclays
- Ionis Pharmaceuticals price target lowered to $40 from $44 at Barclays
- 01/19/23 Piper Sandler
- Ionis Pharmaceuticals price target raised to $62 from $60 at Piper Sandler
- 03/21/23 BofA
- FDA briefing docs suggest FDA in favor of Biogen's tofersen, says BofA
- 03/17/23 Stifel
- Stifel trims Biogen target, but has more confidence lecanemab 'best-in-class'
- 03/13/23 RBC Capital
- Biogen price target raised to $350 from $335 at RBC Capital
- 03/09/23 BofA
- No ad com suggests positive potential outcome for Sage's zura, says BofA
IONS Ionis Pharmaceuticals - 02/22/23
- Ionis Pharmaceuticals sees FY23 revenue $575M, consensus $672.18M
- 02/22/23
- Ionis Pharmaceuticals reports Q4 EPS (37c), consensus (92c)
- 11/09/22
- Ionis Pharmaceuticals backs 2022 revenue above $575M, consensus $594.45M
- 11/09/22
- Ionis Pharmaceuticals reports Q3 EPS (33c), consensus (74c)
- 02/15/23
- Biogen sees FY23 EPS $15.00-$16.00, consensus $15.72
- 02/15/23
- Biogen reports Q4 EPS $4.05, consensus $3.48
- 02/14/23
- Notable companies reporting before tomorrow's open
- 02/14/23
- Notable companies reporting before tomorrow's open
- 03/13/23
- VA to widely cover new Alzheimer's treatment from Eisai and Biogen, STAT says
- 01/11/23
- FDA Commissioner defends FDA's approval of Biogen's Aduhelm, WSJ reports
- 12/23/22
- Third trial death tied to Biogen and Eisai Alzheimer's drug, Science reports
- 11/28/22
- Second death linked to Eisai's lecanemab Alzheimer's drug, Science says
IONS Ionis Pharmaceuticals - 03/24/23
- Buy/Sell: Wall Street's top 10 stock calls this week
- 03/21/23
- Street Wrap: Today's Top 15 Upgrades, Downgrades, Initiations
- 02/15/23
- What You Missed On Wall Street On Wednesday
- 02/15/23
- What You Missed On Wall Street This Morning
- 02/15/23
- Fly Intel: Pre-market Movers
- 01/20/23
- Fly Intel: Pre-market Movers
- 11/30/22
- Early notable gainers among liquid option names on November 30th
- 11/14/22
- Early notable gainers among liquid option names on November 14th
- 10/13/22
- Early notable gainers among liquid option names on October 13th
- 09/29/22
- Unusually active option classes on open September 29th
|
Recommendations
| ShowHide Related Items >><< - 02/07/23
- VF Corp. expects Vans to be down high single digit percentage range in FY23
- 02/07/23
- VF Corp. sees $225M of annualized savings in fiscal 2024
- 02/07/23
- VF commencing strategic alternatives for Global Packs business
- 02/07/23
- VF Corp. cuts quarterly dividend to 30c from 51c per share
- 03/20/23 Williams Trading
- VF Corp. double upgraded to Buy at Williams Trading after management meetings
- 03/20/23 Baird
- VF Corp. price target lowered to $24 from $30 at Baird
- 03/20/23 Williams Trading
- VF Corp. upgraded to Buy from Sell at Williams Trading
- 02/10/23 Stifel
- VF Corp. upgraded to Buy from Hold at Stifel
- 02/07/23
- VF Corp. sees FY24 operating earnings up double-digits
- 02/07/23
- VF Corp. sees FY23 adjusted EPS $2.05-$2.15 vs. prior $2.00-$2.20
- 02/07/23
- VF Corp. reports Q3 adjusted EPS $1.12, consensus 98c
- 02/07/23
- Notable companies reporting after market close
- 03/20/23
- Street Wrap: Today's Top 15 Upgrades, Downgrades, Initiations
- 02/10/23
- What You Missed On Wall Street On Friday
- 02/10/23
- What You Missed On Wall Street This Morning
- 02/10/23
- Street Wrap: Today's Top 15 Upgrades, Downgrades, Initiations
- 03/15/23
- V F Corp call volume above normal and directionally bullish
- 03/10/23
- V F Corp call volume above normal and directionally bullish
- 03/01/23
- V F Corp call volume above normal and directionally bullish
- 02/09/23
- V F Corp put volume heavy and directionally bearish
|
Hot Stocks
| ShowHide Related Items >><< - 03/06/23
- Conduent to showcase fare collection solutions at Transport Ticketing Global
- 02/23/23
- Conduent selected by Virgin Atlantic to support customer experience
- 02/14/23
- Conduent selected by NMHSD to deliver Medicaid Management Information System
- 02/07/23
- Conduent, Genesys partner to enhance customer experience solution
- 05/31/22 Gordon Haskett
- Conduent 'overdue to be sold,' says Gordon Haskett
- 11/01/22
- Conduent sees 2022 revenue $3.85B-$3.95B, consensus $3.91B
- 11/01/22
- Conduent reports Q3 adjusted EPS 9c, consensus 8c
|